Ireland· IE-PA-EU/1/23/1747/001
Enrylaze 10 mg/0.5 mL solution for injection/infusion.
A asparaginase product containing crisantaspase, registered in Ireland by Jazz Pharmaceuticals Ireland Limited. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Asparaginase is registered in 15 of 19 countries.
Countries holding a registration under ATC L01XX02 (asparaginase), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Asparaginase · ATC L01XX02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Crisantaspase
- Manufacturer
- Jazz Pharmaceuticals Ireland Limited
- Country
- Ireland (IE)
- ATC code
- L01XX02
- ATC class
- Asparaginase
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1747/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
280 interactions on record for asparaginase.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Asparaginase · interactions on record
280 records
- 7 severe
- 273 moderate
Most severe, free to view
- ClotrimazoleA01AB18moderate
- Chenodeoxycholic acidA05AA01moderate
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Asparaginase in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumEnrylaze 10 mg/0.5 mlJazz Pharmaceuticals Ireland
- GermanyErwinasePorton Biopharma Limited
- SpainENRYLAZE 10 MG/0,5 ML, SOLUCION INYECTABLE Y PARA PERFUSIONJazz Pharmaceuticals Ireland Limited
- FranceENRYLAZE 10 mg/0,5 mL, solution injectable/pour perfusionJAZZ PHARMACEUTICALS IRELAND LIMITED (IRLANDE)
- NetherlandsEnrylaze 10 mg/0,5 ml oplossing voor injectie/infusieJazz Pharmaceuticals Ireland Ltd.
- NorwayErwinasePorton Biopharma Limided
- PolandEnrylazeJazz Pharmaceuticals Ireland Ltd
- SwedenErwinase 10000 E Pulver till injektions-/infusionsvätska, lösningPorton Biopharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Belgium · Erwinase
- Germany · Erwinase
- Denmark · Erwinase
- Spain · Erwinase
- Finland · Erwinase
- France · Erwinase
- United Kingdom (Northern Ireland) · Erwinase
- Netherlands · Erwinase
- Norway · Erwinase
- Portugal · Erwinase
- Sweden · Erwinase
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b37231a3-a5d7-4d43-beb0-cbaba0f3dbb7 GET /v1/drugs/b37231a3-a5d7-4d43-beb0-cbaba0f3dbb7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection/infusion",
"routes": [
"Intramuscular use",
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01XX02"
],
"strength": null,
"pa_number": "EU/1/23/1747/001",
"substances": [
"Crisantaspase"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "15/09/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about asparaginase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.